Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
Teacher Yasmin Jeevanjee tells her story as a care partner in Kenya.
Featured in the World Alzheimer Report 2018: The state of the art of dementia research: New frontiers, is Dr Jennifer Butte, a formal General Practitioner (GP) diagnosed with dementia. This is her story in her own words.